Efforts to improve traditional ADCs have primarily focused on the three key components: the antibody, the linker, and the payload. Previously, we summarized the research progress in bispecific ADCs. Here, we further consolidate the pipeline updates of dual-payload ADCs.
At the 2025 AACR Annual Meeting, Chinese ADC drugs have emerged in various forms such as bispecific ADCs and dual-toxin ADCs, forming a unique landscape at the AACR meeting. Here, we summarize the key players and target pipelines in the bispecific ADC (BsADC) space, based on AACR data.
The 116th AACR Annual Meeting will be held from April 25 to 30, 2025, at the McCormick Place Convention Center in Chicago, USA. Among the 6,470 abstracts released for the 2025 AACR, there are 340 related to antibody-drug conjugates (ADCs), covering various types such as single-target ADCs, dual-target ADCs, and dual-payload ADCs. These involve numerous […]
In recent years, the rapid development of AI-driven drug discovery (AI-based drug discovery) and Cryo-EM (cryo-electron microscopy) has gradually unveiled the mysteries of many previously considered “undruggable” protein targets. Among them, membrane proteins, which are crucial targets for drug development, are now seeing unprecedented breakthroughs under the dual influence of AI and Cryo-EM technologies. However, membrane protein […]
In recent years, Antibody-Drug Conjugates (ADCs) have gained widespread attention as a key strategy in targeted cancer therapies. The effectiveness of ADCs relies on the specific targeting of the antibody, efficient internalization, and the release of the payload toxin. Therefore, evaluating both the internalization efficiency and cytotoxicity introduced by antibody-payload complex is crucial in ADC […]
The 2025 American Association for Cancer Research (AACR) Annual Meeting is set to take place in Chicago, USA, from April 25 to 30. The recently released conference abstracts highlight the strong presence of Chinese biopharmaceutical companies in the field of antibody-drug conjugates (ADCs). At this year’s conference, Chinese pharmaceutical companies dominate the ADC field, presenting […]
On November 20, 2024, Jazz Pharmaceuticals announced that the bispecific antibody Zanidatamab had received accelerated approval from the FDA for the treatment of adult patients with previously treated, unresectable, or metastatic HER2-positive (HER2+, defined as IHC 3+) biliary tract cancer (BTC). Zanidatamab is the first approved HER2-targeting bispecific antibody with dual epitope specificity. On December […]
1. About (G4S)n Linkers The (G4S)n linker refers to a flexible linker composed of one or more repeating units of G4S (Gly-Gly-Gly-Gly-Ser). Due to its moderate length and flexibility, this linker is widely used in molecular designs requiring the connection of two proteins or peptides. 1.1 Structure Amino Acid Sequence: (Gly-Gly-Gly-Gly-Ser)n Repeating Modules: Composed of […]
1. About Synthetic Nanodisc The lipid composition of traditional membrane scaffold protein (MSP) nanodiscs often differs from that of natural cell membranes, which can lead to deviations in membrane protein properties compared to their native environment. To address this limitation, DIMA has developed the Synthetic Nanodisc platform. This innovative technology enables the direct preparation of […]
Prostate-specific membrane antigen (PSMA) is a pivotal molecular target in the treatment and diagnosis of prostate cancer (PCa). Over the past two decades, extensive research has illuminated its unique molecular characteristics, paving the way for advanced diagnostic and therapeutic approaches. PSMA-targeted imaging techniques, particularly positron emission tomography (PET) radiotracers, have demonstrated exceptional sensitivity in detecting […]